Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | HTR2A | P28223 | 7/20 | 0.43 |
| ▸ | DRD3 | P35462 | 7/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 3/20 | 0.42 |
| ▸ | DRD5 | P21918 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9670880 | 0.89 | CA2 (0.64) | CA2ALDH1A1LMNACA12CA1 | |
| SCHEMBL5252214 | 0.88 | CA2 (0.57) | CA2ALDH1A1LMNAHTTCA12 | |
| SCHEMBL5256127 | 0.86 | CA2 (0.52) | CA2ALDH1A1LMNAHTTMAPK14 | |
| SCHEMBL15013797 | 0.86 | HTR1A (0.47) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL29738634 | 0.81 | ALDH1A1 (0.52) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL3235087 | 0.80 | CA2 (0.56) | CA2ALDH1A1LMNACA12CA1 | |
| SCHEMBL9670928 | 0.79 | CA2 (0.67) | CA2ALDH1A1LMNACA12CA1 | |
| SCHEMBL5979697 | 0.78 | HTR1A (0.43) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL424976 | 0.78 | MAOA (0.53) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL4654113 | 0.78 | HTR1A (0.43) | HTR1ADRD2HTR2ADRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122039074-A | Method for preparing sulfoxide compound by electrochemical microchannel continuous flow oxidation | 南京工业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| CN-100384836-C | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2008-04-30 | — | — | CN | disclosed |
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| CN-1426405-A | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-06-25 | — | — | CN | disclosed |
| EP-0939628-B1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
| US-6013649-A | BOND DISORDERS; AUTOIMMUNE DISEASES; ANTITUMOR AGENTS | MONSANTO COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0939628-A4 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0939628-A1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998003164-A1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | NTSR2, HTR3B, NTSR1 | CA2 2787/4885HTR1A 28/4885DRD2 226/4885 |
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | CA2 3770/4885HTR1A 79/4885DRD2 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.